Depression continues to grapple a large proportion of the population. Given the side effects associated with the long-term use of conventional antidepressants, there is a need for novel rapid acting ...
Russell W. Jenkins, MD, PhD, a physician investigator in the Krantz Family Center for Cancer Research at the Mass General ...
The recent Phase 1a results for their drug TX45 were notably positive, showcasing an excellent safety profile with no ... target, affirming a favorable investment outlook for Tectonic Therapeutic.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback